AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients ...
The author writes "In the realm of insurance coverage litigation, whether two or more claims filed in different time periods ...
Highlights The Delaware Supreme Court took a broad view of relatedness, holding that an SEC investigation and later class ...
The global geriatric care services market is on track for substantial expansion, with a projected Compound Annual Growth Rate (CAGR) of 6.0% from 2022 to 2032. Valued at USD 534 million in 2022, the ...
Financially, Monopar has a cash runway until 2026 but will need additional funds for commercialization efforts. See why I'm ...
New York City’s public pension funds are trying to open a bidding war that could derail Paramount Global’s $8 billion merger ...
The Orphan Drugs Market is experiencing significant growth due to increasing investment in rare disease research, regulatory incentives, and advancements in biotechnology. Orphan drugs are specialized ...
Alexion’s pharmaceutical mission is to transform the lives of people affected by rare diseases and devastating conditions by continuously innovating and creating meaningful value in all that they do.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback